Oxford Biomedica Reported Revenue Growth in First Half
The firm saw 10 percent revenue growth while expanding global manufacturing operations during the reporting period.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Do you trust reports of financial momentum from companies transitioning toward profitability?
Oxford Biomedica recorded revenue of £80.2 million for the six months ending June 30, 2025, marking a 10 percent increase in constant currency. The company also reached 59 active programs while advancing operational initiatives across its global network.
Why it matters
The company is working to improve its financial standing through cost discipline and operational growth. It is currently targeting long-term sustainability and revenue growth goals to be achieved by 2030.
The company reported a revenue backlog of approximately £193 million and now operates 59 active programs. Additionally, the Durham, North Carolina site successfully completed its first GMP manufacturing run.
The players
Oxford Biomedica
This is a gene and cell therapy contract development and manufacturing organization that operates facilities globally.
The details
Oxford Biomedica enhanced its global contract development and manufacturing organization capabilities across sites in the United Kingdom, France, and Bedford, Massachusetts. The improvement in adjusted operating EBITDA was driven by a combination of consistent revenue growth and corporate cost discipline.
Timeline
The financial reporting period concluded on June 30, 2025.
The firm executed its commercial strategy through the first half of 2026.
Sustainable profitability and revenue targets are set for 2030.
The Tech Race
The expansion of GMP capabilities in North Carolina reflects the broader industry shift toward decentralized manufacturing capacity for complex therapies. This strategy positions Oxford Biomedica to compete in the crowded market for outsourced bioprocessing services.
The firm's operational growth and expanded manufacturing capacity increase the likelihood of bringing complex gene therapies to market. For researchers and partners, the milestone in North Carolina improves access to scalable GMP production services.
The takeaway
The company is balancing increased investment in manufacturing facilities with a clear focus on long-term fiscal discipline. Investors and stakeholders should monitor whether these operational gains continue to narrow the EBITDA gap toward the 2030 profitability goal.
Further reading
For more information on current developments, visit the Biotech section.
Live Poll
Do you trust reports of financial momentum from companies transitioning toward profitability?
